Navigation Links
NASCSA Receives $200,000 Grant from Purdue Pharma L.P. to Support State Prescription Drug Monitoring Programs
Date:10/18/2011

PORTLAND, Maine, Oct. 18, 2011 /PRNewswire/ -- The National Association of State Controlled Substances Authorities (NASCSA) announced receipt of a $200,000 grant from Purdue Pharma L.P. today at the organization's 27th annual conference in Portland, Maine. The grant is part of Purdue Pharma's ongoing efforts to support the operation, expansion and awareness of appropriately-designed state prescription drug monitoring programs, which can be an effective tool to address prescription drug abuse and diversion. Purdue has supported NASCSA efforts to strengthen and fund state PMPs for the last three years.

NASCSA will manage the solicitation, review and funding of grant proposals. State government agencies or departments will be selected based on an independent review by the NASCSA Special Projects Committee, which consists of association members with expertise in the fields of prescription drug abuse and diversion and prescription drug monitoring programs. Purdue Pharma will have no input into the final selection process.  

"State budgets are shrinking, but the abuse and diversion of prescription drug problem is a growing concern, said Ralph Orr, NASCSA secretary, treasurer and special projects chairman. "Purdue Pharma's funding of state prescription drug monitoring programs will help keep these medications out of the wrong hands while ensuring legitimate patients have access to the medications they need."

The grant monies are scheduled to be distributed by NASCSA to various state government departments or agencies with the ability to accept private funding expressly for their state prescription monitoring program by the end of 2012.

"Since 2001, Purdue Pharma has been working to support the implementation of appropriately-designed prescription monitoring programs as one way to help reduce abuse and diversion of prescription medications," said Alan Must, vice president of state government and public affairs at Purdue Pharma. "Reducing the abuse of prescription medications will take the combined and coordinated efforts of healthcare professionals, law enforcement, government agencies and local communities. NASCSA is an organization that is uniquely qualified to address the issues of prescription drug abuse from a broad inclusive perspective and we are delighted to provide this funding for this initiative."

The National Association of State Controlled Substances Authorities is a 501(C)(3) non-profit educational organization whose primary purpose is to provide a continuing mechanism through which state and federal agencies can work to increase the effectiveness and efficiency of efforts to prevent and control drug diversion and abuse. NASCSA can be found at www.nascsa.org.

Purdue Pharma L.P. and its associated U.S. companies are privately-held pharmaceutical companies known for pioneering research on persistent pain. Headquartered in Stamford, CT, Purdue Pharma is engaged in the research, development, production, and distribution of both prescription and over-the-counter medicines and hospital products. Additional information about Purdue can be found at www.purduepharma.com.


'/>"/>
SOURCE National Association of State Controlled Substances Authorities
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. NASCSA Receives $200,000 Grant From Purdue Pharma L.P. to Support State Prescription Drug Monitoring Programs
2. NASCSA Receives $200,000 Grant From Purdue Pharma L.P. to Support State Prescription Drug Monitoring Programs
3. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
4. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
5. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
6. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
7. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
8. CryoCor Receives FDA Approval for Right Atrial Flutter
9. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
10. Dimericine(R) Receives FDA Fast Track Designation for Treatment Of Photosensitivity in XP Patients
11. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... , Oct. 12, 2017 AVACEN Medical , ... company with their  2017 New Product Innovation Award for ... extensive primary and secondary medical device market research by Frost ... its first-to-market OTC, drug-free pain relief product, the AVACEN 100, ... to treating fibromyalgia widespread pain. ...
(Date:10/11/2017)...  True Health, a leader in integrated diagnostics ... National Breast Cancer Awareness month to educate doctors ... Research recently published in ... than 10 million American women are at significant ... BRCA2 and have not had testing. These mutations can ...
(Date:10/5/2017)... 2017  In response to the nationwide opioid ... Surgeons (AAOMS) released prescribing recommendations that urge ibuprofen ... as a first-line therapy to manage a patient,s ... Recognizing the value and importance of ... Prescribing: Acute and Postoperative Pain Management" stresses that ...
Breaking Medicine Technology:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Many families ... However, many long-term care insurance companies have a waiver for care if the client ... elimination period, when the family pays for care, is often waived, so the benefits ...
(Date:10/13/2017)... ... ... Talented host, actor Rob Lowe, is introducing a segment ... of "Success Files," which is an award-winning educational program broadcasted on PBS Member ... with passion and integrity. , Sciatica occurs when the sciatic nerve in the ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... now treating sleep apnea using cutting-edge Oventus O2Vent technology. As many ... sleep disorder characterized by frequent cessation in breathing. Oral appliances can offer significant ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... AccentCare, a leader in post-acute health care, have expanded their existing home health ... Home Health. , AccentCare has been operating a joint venture home health company ...
(Date:10/12/2017)... ... October 12, 2017 , ... On Saturday, October 21, the Health & ... by Moonlight to raise money for the American Heart Association Heart Walk. Teams of ... will work together to keep their treadmills moving for 5 hours. Treadmills will start ...
Breaking Medicine News(10 mins):